Insurance Denied Zepbound® or Wegovy®: What Are Your Options Now?
A denial is rarely the end of the road. It is a fork with four paths: fix the paperwork and appeal, switch to a covered alternative, use a manufacturer self-pay program, or be evaluated for other physician-prescribed options. Which path fits depends on why you were denied, and the denial letter tells you.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 9 min read
Key facts
Denials come in kinds: missing documentation, step-therapy requirements, a formulary preference for a different GLP-1, or a plan that excludes weight loss drugs entirely. The fix is different for each.
Only a small fraction of denials are ever appealed, and appeals of fixable denials succeed often enough to be worth the letter.
A plan-level exclusion of weight loss medication usually cannot be appealed into coverage. Self-pay channels are the realistic route.
Several large pharmacy benefit managers changed which GLP-1 they prefer during 2025 and 2026, forcing switches between brands mid-treatment.
Manufacturer direct programs now sell the branded injectables self-pay at prices far below list.
First: which kind of denial did you get?
Read the denial letter for the stated reason. It sorts into one of four buckets. A documentation denial means the prior authorization lacked something checkable: a qualifying BMI reading, a comorbidity diagnosis code, records of previous weight management attempts. A step-therapy denial means the plan wants you to try, or to have documented trying, something else first. A formulary denial means the plan covers a different GLP-1 than the one prescribed. An exclusion means your plan does not cover weight loss medication for anyone, at any BMI, with any paperwork.
Everything that follows depends on that sorting, which is why the letter matters more than anything a forum tells you.
When is an appeal actually worth it?
Documentation and step-therapy denials are the appealable kind. If the chart genuinely supports the criteria, a resubmission with the missing evidence, a corrected code, an updated BMI, a documented history, succeeds often enough that skipping it leaves money on the table. Very few patients bother: industry figures put appeals at under one percent of denials, which mostly measures exhaustion, not merit.
Exclusions are the other story. If the plan document says weight loss medication is not a covered benefit, an appeal is asking the plan to rewrite the policy, which internal review will not do. Your realistic moves are the ones outside the plan.
What if my plan covers a different GLP-1 than the one I want?
Formulary preference switches became a defining feature of 2025 and 2026: some large pharmacy benefit managers dropped one branded injectable in favor of the other, and patients mid-treatment were told their next fill would be a different medication. Frustrating as that is, a forced switch between the two branded injectables is a clinically manageable event that physicians handle routinely, with a dose mapping rather than a restart from zero in many cases.
If you are facing one, the questions that matter are covered in our switching guide: what dose you land on, what happens to side effects during the transition, and what to watch in the first weeks.
3/mo CHROMA23+ Membership unlocks it at one clear price, medication priced separately and always shown.
Are there coverage side doors worth knowing about?
Sometimes the same molecule is covered under a different indication. Tirzepatide is approved separately for type 2 diabetes as Mounjaro®, and Zepbound® carries an approval for obstructive sleep apnea in adults with obesity. Semaglutide's cardiovascular indication plays a similar role for some plans. If you have one of those diagnoses, coverage may exist where the weight loss indication alone was denied. This is a conversation for your physician, since the diagnosis, the documentation, and the prescription all have to match your actual clinical picture.
What is not a side door: pressuring a physician to code a condition you do not have. That is fraud, physicians know it, and platforms built on it do not last.
What does self-pay actually look like after a denial?
Three channels, covered in detail in our cost guide. The manufacturer direct programs sell the branded injectables at tiered self-pay prices well below list, typically as vials. The new oral GLP-1 tablets launched with introductory self-pay pricing that undercuts the injectables, at least at first fill. And patient-specific compounded tirzepatide from state-licensed pharmacies remains available when a physician documents a clinical need, at prices that generally sit below branded tiers.
The right channel depends on your dose, your format preference, and your clinical situation, which is exactly what a physician evaluation is for. A denial changes who pays. It does not change the medicine's appropriateness for you, and it does not have to end treatment.
Frequently asked questions
My employer plan excludes all weight loss drugs. Is there any point appealing?
Internal appeals cannot add a benefit the plan excludes. What occasionally works is the employer channel: benefits teams do add GLP-1 coverage year to year, and documented employee demand is part of why. For treatment now, the self-pay channels are the realistic path.
Does Medicare cover GLP-1s for weight loss?
Medicare has historically been barred from covering drugs for weight loss alone, while covering some GLP-1s under diabetes, cardiovascular, and sleep apnea indications. Policy on this has been actively debated for years, and one manufacturer launched a discount card aimed at Medicare patients for its oral tablet. Check current program terms rather than assuming either way.
How fast can I restart treatment if I move to self-pay?
There is no forced gap. A physician evaluation, a prescription through the channel that fits, and a fill are the whole sequence. If you were mid-titration when coverage ended, tell the physician your last dose and date so the restart is mapped rather than guessed.
Can CHROMA23® help if I was denied?
That is a common way people arrive. The assessment is free, a board-certified physician reviews whether treatment is appropriate for you, and the 3/mo CHROMA23+ Membership unlocks physician-prescribed options with every cost shown up front. No insurance is involved, so a denial letter is irrelevant to eligibility.
About CHROMA23®
CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.